Aadi Bioscience, Inc. ( (WHWK) ) has released its Q3 earnings. Here is a breakdown of the information Aadi Bioscience, Inc. presented to its investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Whitehawk Therapeutics, Inc. is an oncology therapeutics company focused on developing advanced antibody drug conjugate (ADC) cancer treatments by leveraging established tumor biology and innovative technologies. The company aims to address difficult-to-treat cancers with its engineered ADC portfolio.
In its third-quarter 2025 financial report, Whitehawk Therapeutics highlighted its strategic progress and financial performance. The company is on track with its planned Investigational New Drug (IND) filings for HWK-007 and HWK-016 by the end of the year, and it has maintained a strong financial position to support its clinical development plans.
Key financial metrics from the report include a significant increase in cash, cash equivalents, and short-term investments to $162.6 million as of September 30, 2025, compared to $47.2 million at the end of 2024. The net loss for the quarter was $17.7 million, up from $12.5 million in the same period last year, reflecting increased research and development expenses.
Operational highlights include the presentation of a real-world analysis confirming PTK7 as a relevant target across solid tumors, and the company remains focused on bringing all three assets to IND by mid-2026. The cash position is expected to fund operations into 2028, allowing for initial clinical data readouts across the portfolio.
Looking ahead, Whitehawk Therapeutics is poised to advance its ADC assets through clinical development, with management expressing confidence in achieving value-creating milestones and addressing the needs of patients with PTK7-expressing cancers.